Ligand Pharmaceuticals (LGND)
(Delayed Data from NSDQ)
$115.45 USD
-6.63 (-5.43%)
Updated Nov 14, 2024 04:00 PM ET
After-Market: $115.48 +0.03 (0.03%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$115.45 USD
-6.63 (-5.43%)
Updated Nov 14, 2024 04:00 PM ET
After-Market: $115.48 +0.03 (0.03%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Shire (SHPG) Q1 Earnings Beat, Rare Disease Franchise Strong
by Zacks Equity Research
Shire (SHPG) reports better-than-expected first-quarter earnings and records strong growth in immunology franchise and newly launched products.
Sanofi's (SNY) Earnings Beat Estimates in Q1, Sales Miss Mark
by Zacks Equity Research
Sanofi (SNY) beat earnings but missed sales estimates in the first quarter of 2018 owing to exchange rate effects and struggling diabetes and cardiovascular unit.
Vertex (VRTX) Q1 Earnings Beat on Strong CF Products Sales
by Zacks Equity Research
Vertex Pharma (VRTX) first-quarter earnings increase from the year-ago period led by strong sales trend of CF drugs.
AbbVie (ABBV) Q1 Earnings Beat, 2018 View Up, Stock Gains
by Zacks Equity Research
AbbVie's (ABBV) Q1 earnings top estimates with revenues marginally beating the same. Sales of the company's lead marketed drug, Humira, also rise year over year.
Alexion's (ALXN) Earnings Beat Estimates in Q1, Guidance Up
by Zacks Equity Research
Alexion exceeds both earnings and sales expectations in the first quarter of 2018.The company also raised revenue and earnings guidance for 2018.
BioMarin (BMRN) Q1 Earnings Lower Than Expected, Sales Beat
by Zacks Equity Research
BioMarin (BMRN) reported mixed first-quarter results with earnings missing estimates but sales beating the same.
Catalyst Enrolls First Patient in Phase III Firdapse Study
by Zacks Equity Research
Catalyst (CPRX) enrolls the first patient in its phase III clinical trial (MSK-002) to evaluate the efficacy and safety of Firdapse in patients with MuSK antibody positive Myasthenia Gravis.
Bristol-Myers' Opdivo Gets Priority Review for Lung Cancer
by Zacks Equity Research
The FDA accepts Bristol-Myers Squibb's (BMY) supplemental Biologics License Application and grants priority review for the label expansion of Opdivo to treat patients with small cell lung cancer.
Calithera's Kidney Cancer Candidate Gets Fast Track Status
by Zacks Equity Research
Calithera Biosciences' (CALA) lead pipeline candidate, CB-839, gets fast track status in the United States for the treatment of kidney cancer.
Bayer to Divest 3.6% Stake to Singapore Company Temasek
by Zacks Equity Research
Bayer (BAYRY) will divest its 3.6% stake to Singapore's state investment company Temasek for total gross proceeds of ???3 billion.
Agios' Leukemia Drug Bodes Well for Growth & Strong Pipeline
by Zacks Equity Research
The FDA approval for Agios' (AGIO) only marketed drug, Idhifa, augurs well for long-term growth. The company is also well on progress track with its lead candidate, ivosidenib, for R/R AML.
Alnylam (ALNY) Reports Positive Data for RNAi Candidate
by Zacks Equity Research
Alnylam (ALNY) announced encouraging results from phase I and phase I/II open-label extension studies of givosiran, which is being evaluated for the treatment of acute hepatic porphyrias.
Alkermes Rallies as FDA Accepts NDA for Depression Drug
by Zacks Equity Research
Shares of Alkermes (ALKS) rose when the FDA accepted for review the new drug application for its depression candidate ALKS 5461 two weeks after it had issued a Refusal to File letter.
Merck's Keytruda Betters Survival in Lung Cancer Combo Study
by Zacks Equity Research
Merck (MRK) releases complete data from a phase III study showing Keytruda in combination with Lilly's Alimta and platinum chemotherapy reducing death risk by half compared with only chemotherapy.
Intercept Reports Phase III Sub-Study Liver Biopsy Data
by Zacks Equity Research
Intercept (ICPT) announces data from the POISE biopsy sub-study which showed that treatment with obeticholic acid leads to the reversal or stabilization of fibrosis/cirrhosis in patients with primary biliary cholangitis.
Rigel Pharmaceuticals' (RIGL) Stock Gains 16%: Here's Why
by Zacks Equity Research
Shares of Rigel (RIGL) rise given that the FDA's decision on its lead pipeline candidate Tavalisse is nearing.
Verastem (VSTM) in Focus: Stock Moves 8% Higher
by Zacks Equity Research
Shares of Verastem (VSTM) rose nearly 8% yesterday.
FDA Lifts Clinical Hold on Bellicum's (BLCM) T Cell Therapy
by Zacks Equity Research
Bellicum (BLCM) agrees to make amendments to the protocols relating to clinical studies evaluating its T Cell Therapy, BPX-501.
Zacks.com featured highlights include: Ligand, ArcelorMittal, 58.com, Ameresco and Mammoth Energy
by Zacks Equity Research
Zacks.com featured highlights include: Ligand, ArcelorMittal, 58.com, Ameresco and Mammoth Energy
Epizyme (EPZM) Publishes Tazemetostat Phase I Data, Stock Up
by Zacks Equity Research
Epizyme (EPZM) publishes tazemetostat phase I clinical data in The Lancet Oncology. The study demonstrated favorable safety findings and anti-tumor activity.
Karyopharm's Myeloma Candidate Gets Fast Track Designation
by Zacks Equity Research
The FDA grants a fast track status to Karyopharm's (KPTI) selinexor for treatment of multiple myeloma. Selinexor is also evaluated in several mid- and later-phase studies on multiple cancer indications.
FDA Prolongs Review Date for AbbVie Endometriosis Candidate
by Zacks Equity Research
The FDA extends the review period of NDA for AbbVie (ABBV) and partner Neurocrine Biosciences' endometriosis candidate, elagolix, by three months to third-quarter 2018.
5 Best Profitable Stocks Offering Amazing Returns
by Zacks Equity Research
Net income ratio gives us the exact profitability level of a company and reflects the percentage of net income to total sales revenues.
FDA Restricts Sale of Bayer's Essure Birth Control Device
by Zacks Equity Research
FDA puts restriction on the sale of Bayer's (BAYRY) implanted birth control device Essure.
Ionis (IONS) Clinches Licensing Agreement with AstraZeneca
by Zacks Equity Research
Ionis (IONS) inks a licensing deal with AstraZeneca per which the former will license IONIS-AZ6-2.5-LRx to AstraZeneca for the treatment of NASH.